Mizuho Lowers LivaNova (NASDAQ:LIVN) Price Target to $60.00

LivaNova (NASDAQ:LIVN) had its target price dropped by stock analysts at Mizuho from $70.00 to $60.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s price target would suggest a potential upside of 46.59% from the stock’s previous close.

Other analysts have also issued research reports about the stock. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. Needham & Company LLC lowered their price objective on LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday. Stifel Nicolaus dropped their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday. Finally, Robert W. Baird raised their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, LivaNova presently has an average rating of “Buy” and a consensus target price of $64.20.

LivaNova Trading Down 1.3 %

Shares of LIVN opened at $40.93 on Wednesday. LivaNova has a twelve month low of $40.37 and a twelve month high of $64.47. The stock has a market cap of $2.22 billion, a PE ratio of 97.45 and a beta of 1.00. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The business’s 50-day moving average price is $47.52 and its 200-day moving average price is $49.50.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is owned by insiders.

Institutional Trading of LivaNova

A number of hedge funds have recently bought and sold shares of LIVN. Jefferies Financial Group Inc. bought a new position in LivaNova during the fourth quarter valued at approximately $4,812,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of LivaNova by 25.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 153,458 shares of the company’s stock valued at $7,107,000 after purchasing an additional 30,718 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of LivaNova by 74.3% during the 4th quarter. Squarepoint Ops LLC now owns 111,449 shares of the company’s stock valued at $5,161,000 after purchasing an additional 47,494 shares during the last quarter. Two Sigma Advisers LP raised its position in LivaNova by 148.5% in the 4th quarter. Two Sigma Advisers LP now owns 214,545 shares of the company’s stock worth $9,936,000 after purchasing an additional 128,200 shares during the period. Finally, Two Sigma Investments LP lifted its stake in LivaNova by 27.2% in the fourth quarter. Two Sigma Investments LP now owns 439,582 shares of the company’s stock worth $20,357,000 after purchasing an additional 93,985 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.